| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037761420 |
| P356 | DOI | 10.1038/SJ.ONC.1208744 |
| P698 | PubMed publication ID | 15897870 |
| P5875 | ResearchGate publication ID | 7843390 |
| P50 | author | Brooke T. Mossman | Q28112928 |
| P2093 | author name string | Agnes B Kane | |
| Joseph R Testa | |||
| Suresh C Jhanwar | |||
| Assunta De Rienzo | |||
| Huihong You | |||
| Maria E Ramos-Nino | |||
| Guang-Hui Xiao | |||
| Deborah A Altomare | |||
| Kristine L Skele | |||
| P2860 | cites work | High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 |
| Mechanisms of resistance to rapamycins | Q28198092 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. | Q33869038 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma | Q33946963 | ||
| SV40 and the pathogenesis of mesothelioma | Q34177994 | ||
| Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 | ||
| Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy | Q34306865 | ||
| Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Q35046899 | ||
| PTEN signaling pathways in melanoma | Q35146572 | ||
| Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model | Q35147039 | ||
| eIF4E--from translation to transformation | Q35750110 | ||
| Lost in translation: dysregulation of cap-dependent translation and cancer | Q35802625 | ||
| Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells | Q40546587 | ||
| The mRNA 5' cap-binding protein eIF4E and control of cell growth | Q41751015 | ||
| Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases | Q41972231 | ||
| AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth | Q42463490 | ||
| Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma | Q43802258 | ||
| Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. | Q47733896 | ||
| Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer | Q73816430 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| pharmacology | Q128406 | ||
| P304 | page(s) | 6080-6089 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth | |
| P478 | volume | 24 |
| Q34018570 | A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma |
| Q36952781 | A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells. |
| Q91081380 | ADAM10 mediates malignant pleural mesothelioma invasiveness |
| Q37101238 | Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q34340354 | Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. |
| Q35684875 | An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. |
| Q36571864 | Animal models of malignant mesothelioma |
| Q43239330 | Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo |
| Q28393611 | Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways |
| Q35748646 | Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models |
| Q37328307 | Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. |
| Q37316834 | Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma |
| Q28391676 | Cellular and molecular parameters of mesothelioma |
| Q33476900 | Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis |
| Q57071216 | Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q90133145 | Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity |
| Q34471229 | Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas |
| Q36081391 | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis |
| Q40032657 | Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q40080013 | HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway |
| Q51795590 | HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis. |
| Q37880216 | Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation |
| Q64376949 | Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas |
| Q37526974 | Induction of tunica vaginalis mesotheliomas in rats by xenobiotics |
| Q37130217 | Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma |
| Q36346942 | Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors |
| Q35598236 | Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy |
| Q38849618 | Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells. |
| Q36600294 | Investigating mammalian target of rapamycin inhibitors for their anticancer properties |
| Q28390539 | Malignant mesothelioma: facts, myths, and hypotheses |
| Q39864601 | Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q36741548 | Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids |
| Q92973379 | Mesothelium and Malignant Mesothelioma |
| Q91826299 | Metabolic rewiring and redox alterations in malignant pleural mesothelioma |
| Q39001426 | Multipoint targeting of the PI3K/mTOR pathway in mesothelioma |
| Q55355075 | NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q39501588 | New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization |
| Q28389555 | Non-neoplastic and neoplastic pleural endpoints following fiber exposure |
| Q28385588 | Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions |
| Q37855667 | Novel targeted therapies and vaccination strategies for mesothelioma |
| Q34360248 | Overview of the biochemical and genetic processes in malignant mesothelioma. |
| Q38398970 | PTEN protein expression in malignant pleural mesothelioma |
| Q37975137 | Pathological and molecular biological approaches to early mesothelioma |
| Q34271064 | Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma |
| Q36313181 | Perturbations of the AKT signaling pathway in human cancer |
| Q53633854 | Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. |
| Q28396403 | Pleural mesothelial cells in pleural and lung diseases |
| Q39463417 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin |
| Q36159154 | Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma |
| Q28115391 | Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor |
| Q52722394 | RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines. |
| Q23917646 | Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappa B, and Akt in normal and malignant human mesothelial cells |
| Q28392665 | Reactive oxygen species a double-edged sword for mesothelioma |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q36189820 | Role of Merlin/NF2 inactivation in tumor biology |
| Q28389566 | Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases |
| Q35006450 | SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM) |
| Q38365768 | Searching for targets for the systemic therapy of mesothelioma. |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q44802535 | The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance |
| Q39971024 | The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells |
| Q38148036 | The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms |
| Q37454384 | The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. |
| Q33878064 | Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q37597672 | Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma |
| Q41878253 | Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells |
| Q39977210 | mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids |
Search more.